ERGO (Entia Biosciences) Long-Term Debt: $0.30 Mil (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entia Biosciences Long-Term Debt?

Entia Biosciences ERGO Long-Term Debt is $0.30 Mil as of Dec. 2016.

Entia Biosciences's Long-Term Debt for the quarter that ended in Dec. 2016 was $0.30 Mil.

Entia Biosciences's quarterly Long-Term Debt increased from Jun. 2016 ($0.30 Mil) to Sep. 2016 ($0.30 Mil) and increased from Sep. 2016 ($0.30 Mil) to Dec. 2016 ($0.30 Mil).

Entia Biosciences's annual Long-Term Debt stayed the same from Dec. 2014 ($0.00 Mil) to Dec. 2015 ($0.00 Mil) but then increased from Dec. 2015 ($0.00 Mil) to Dec. 2016 ($0.30 Mil).

Entia Biosciences  (OTCPK:ERGO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Entia Biosciences Long-Term Debt Related Terms

Entia Biosciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences Long-Term Debt Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.30

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.15 0.30 0.30 0.30
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.30 Mil mean?
Entia Biosciences (ERGO) has a Long-Term Debt of $0.30 Mil as of Dec. 2016.
Is Entia Biosciences' Long-Term Debt too high?
Entia Biosciences' current Long-Term Debt is $0.30 Mil.
How does Entia Biosciences' Long-Term Debt compare to OBMP and NSPX?
Entia Biosciences' Long-Term Debt of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Entia Biosciences's current Long-Term Debt is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Long-Term Debt of $0.30 Mil. The current Long-Term Debt is $0.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Long-Term Debt is $0.30 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.